BM Pekao on Wednesday upgraded Poland-based energy group Orlen (PKN.WA) to buy from hold and raised its price target to 166.58 Polish zlotys from 126.16 zlotys.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Gold Fields (GFI) has an average rating of overweight and mean price target of $58.63, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CIBC Capital Markets raised its price target on Well Health Technologies (WELL.TO) to $6 from $5.50.Analyst Eric Kyle maintained an Outperformer rating on shares of the Vancouver-based digital health technology company."WELL announced the company has reached its $100 Million annualized adjusted EBITDA target for WELL Canada (Canadian clinics, WELLSTAR, and CYBERWELL) three quarters ahead of plan, in Q2/26 compared to Q1/27 expectations, driven by strong primary care organic growth and two accretive acquisitions," Kyle said in a note to clients."The company acquired an Ontario diagnostics imaging clinic and a Quebec procedural care clinic for $115 Million upfront, generating $22 Million of combined adjusted EBITDA, implying ~5x EBITDA on close," the analyst said."We expect management will increase 2026 guidance when WELL reports Q2 results in August."
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:M reported adjusted Q1 FY 27 (Jan.) EPS of $0.13 vs. $0.16 prior year, $0.10 above consensus estimates, on net sales of $4.682B (+1.8% Y/Y) and $70M above estimates. Comparable sales growth of 3.0% marked the strongest Q1 performance in four years and the fourth consecutive quarter of gains. The quarter showed broad-based strength with Bloomingdale's leading at 10.2% comparable sales growth, Macy's nameplate delivering 1.6% growth, and Bluemercury contributing 6.4% growth. Management raised full-year guidance with net sales of $21.5B-$21.75B, comparable sales of +0.5% to +1.2%, and adjusted EPS of $2.00-$2.20. The company returned $100M to shareholders while maintaining $1.3B in cash and a strong balance sheet position. Shares trade around 10x full-year EPS guidance, well above its three- and five-year forward P/E multiples of 7.0x and 6.5x, respectively. In our opinion, this was a typical quarter where sales growth didn't lead to margin expansion, and we do not see a big margin expansion story ahead.